Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mark A Spahr"'
Autor:
Sergey Filippov, Stephen L. Pinkosky, Richard J. Lister, Catherine Pawloski, Jeffrey C. Hanselman, Clay T. Cramer, Rai Ajit K. Srivastava, Timothy R. Hurley, Cheryl D. Bradshaw, Mark A. Spahr, Roger S. Newton
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 8, Pp 2095-2108 (2013)
ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates le
Externí odkaz:
https://doaj.org/article/5dade5c025dd481597a6c9e3ada9030c
Autor:
Stephen L. Pinkosky, Sergey Filippov, Rai Ajit K. Srivastava, Jeffrey C. Hanselman, Cheryl D. Bradshaw, Timothy R. Hurley, Clay T. Cramer, Mark A. Spahr, Ashley F. Brant, Jacob L. Houghton, Chris Baker, Mark Naples, Khosrow Adeli, Roger S. Newton
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 1, Pp 134-151 (2013)
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk factors. The hypolipidemic, anti-atherosclerotic, anti-obesity, and gluc
Externí odkaz:
https://doaj.org/article/cec4f54dcb2f41e99d4df80fe4b930fe
Autor:
Chuck A. Lesch, Ling Yang Hao, Ivan Monteleone, Anthony W. Opipari, Wenpu Zhao, Oksana Mashadova, Gary D. Glick, Mark A. Spahr, John M. Asara, Giovanni Monteleone, Costas A. Lyssiotis, Brian Sanchez, Irene Marafini, Luigi Franchi, Xiao Hu, Kellie Demock, Xikui Liu, Min Yuan, Harinder Singh, Aditi Kulkarni, Laura L. Carter
Publikováno v:
The Journal of Immunology. 198:2735-2746
Integration of signaling and metabolic pathways enables and sustains lymphocyte function. Whereas metabolic changes occurring during T cell activation are well characterized, the metabolic demands of differentiated T lymphocytes are largely unexplore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fba90584d43c28b544a24097ef938ec6
https://doi.org/10.4049/jimmunol.1600810
https://doi.org/10.4049/jimmunol.1600810
Autor:
Cheryl D. Bradshaw, Sergey Filippov, Clay T. Cramer, Catherine Pawloski, Mark A. Spahr, Stephen L. Pinkosky, Timothy R. Hurley, Rai Ajit K. Srivastava, Richard J Lister, Roger S. Newton, Jeffrey C. Hanselman
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 8, Pp 2095-2108 (2013)
ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af69809908d091df0e381593e8a69ea9
http://www.sciencedirect.com/science/article/pii/S002222752037526X
http://www.sciencedirect.com/science/article/pii/S002222752037526X
Autor:
Mark A. Spahr, Jeffrey C. Hanselman, Roger S. Newton, Rai Ajit K. Srivastava, Mark Naples, Clay T. Cramer, Stephen L. Pinkosky, Timothy R. Hurley, Khosrow Adeli, Jacob L. Houghton, Sergey Filippov, Cheryl D. Bradshaw, Ashley F. Brant, Christopher Baker
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 1, Pp 134-151 (2013)
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk factors. The hypolipidemic, anti-atherosclerotic, anti-obesity, and gluc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d7951a1d094c9e3e8454ac8eafbe26
https://doi.org/10.1194/jlr.m030528
https://doi.org/10.1194/jlr.m030528
Autor:
Randy Ramharack, Peggy Liao, Janak Khimchand Padia, Bruce D. Roth, Patt William Chester, Helen Tsenwhei Lee, Mark A Spahr, Jason K. Pontrello, Karen Elaine Sexton, Mark A. Massa
Publikováno v:
Bioorganic & Medicinal Chemistry. 11:4827-4845
Compounds of the general structure A and B were investigated for their activity as lipoprotein(a), [Lp(a)], assembly (coupling) inhibitors. SAR around the amino acid derivatives (structure A) gave compound 14-6 as a potent coupling inhibitor. Oral do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a8eb8e08ad1868ff21ba683a1dd33e9
https://doi.org/10.1016/j.bmc.2002.04.001
https://doi.org/10.1016/j.bmc.2002.04.001
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1438:322-328
Lipoprotein (a) [Lp(a)] is a heterodimer of apolipoprotein (a) [apo(a)] and apolipoprotein B-100 (apoB-100) of low density lipoprotein linked by a disulfide bond. Apo(a) and apoB-100 are synthesized by the liver and covalently associate or couple to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022a0217fd6cfc6a7240154152315966
https://doi.org/10.1016/s1388-1981(99)00065-7
https://doi.org/10.1016/s1388-1981(99)00065-7
Autor:
Mark A. Spahr, William T. Mueller, Randy Ramharack, Fu-Zon Chung, Lan-Hsin Wu, Ye Tian, Dale L. Oxender, Helen T. Lee, Philip D. Settimi, Scott R. Eaton
Publikováno v:
Protein Expression and Purification. 13:222-228
Elevated plasma lipoprotein(a) [Lp(a)] is an independent risk factor for several vascular diseases. Lp(a) particles are generated through the formation of a disulfide bond between Cys 4057 of kringle IV type 9, (KIVt9), of the multikringle apolipopro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4255e947ef827422e853f6615e7def55
https://doi.org/10.1006/prep.1998.0898
https://doi.org/10.1006/prep.1998.0898
Autor:
Brian K Krause, Mark A. Spahr, Randy Ramharack, Helen T. Lee, R. F. Bousley, Catherine S. Sekerke, R. L. Stanfield
Publikováno v:
Atherosclerosis. 136:79-87
Lipoprotein(a) (Lp(a)), which is generated through the covalent association of apolipoprotein(a) (apo(a)) and apo B-100-LDL, is an independent risk factor for several vascular diseases. Therefore, there is interest in developing therapies for lowerin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c01a16b8e190e230c9a16bfc90ea3d
https://doi.org/10.1016/s0021-9150(97)00189-5
https://doi.org/10.1016/s0021-9150(97)00189-5
Publikováno v:
Biochemical and Biophysical Research Communications. 238:48-52
Elevated plasma lipoprotein(a) [Lp(a)] independently contributes to a variety of vascular diseases; consequentially, factors that modulate its levels are of interest. Since Lp(a) is produced by a disulfide linkage between apolipoprotein(a) [apo(a)] a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa3d9bf3e681ef5d39366d84d7f570f
https://doi.org/10.1006/bbrc.1997.7240
https://doi.org/10.1006/bbrc.1997.7240